Therapeutics Company Announce FDA Acceptance For New Galactosemia Treatment

In a significant development for the healthcare sector and investors worldwide, Applied Therapeutics Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company, has announced the Food and Drug Administration's acceptance and priority review of their New Drug Application (NDA) for Govorestat for the treatment of Classic Galactosemia. Furthermore, the company has declared a $100 million private placement, making it a focal point for both patients and investors. $Applied Therapeutics(APLT.US)$